Patient case: 64-year-old male with bladder cancer; genetic feature: FGFR3 (S249C)

Clinical trial: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Summary: The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined.


Eligibility: Inclusion Criteria:
  Part A - single-agent dose-escalation part:
  - Patients with histologically confirmed solid tumors or non-Hodgkin's lymphoma (NHL).
  J-arm of Part A - single-agent doseescalation in Japanese
  - Japanese patients with histologically confirmed solid tumors. Patients with tumors known to be positive for DDR (deoxyribonucleic acid damage repair) defects (such as ATM (ataxia-telangiectasia mutated) deleterious mutation or low ATM expression) can be included.
  Part B - single-agent expansion part:
  -  Patients with DDR deficiency biomarker-positive advanced solid tumors of the following histologies: i) CRPC (castration-resistant prostate cancer); ii) HER2-negative BC that is hormone-receptor positive (estrogen-receptor positive, progesterone-receptor positive, or both) or TNBC (triple negative BC); iii) CRC (colorectal cancer), and iv) gynecological tumors (ovarian, primary peritoneal, and fallopian tube cancers, endometrial cancer, or cervical cancer). The biomarker status of patients in Part B will be evaluated before general screening and only patients with the presence of the putative biomarkers of DDR deficiency will be recruited into general screening.
  -  Patients with histologically confirmed advanced cancer and loss of ATM protein by IHC, regardless of the cancer type.
  The following inclusion criteria apply to ALL (dose-escalation and expansion) patients:
  -  Patients with tumors resistant or refractory to standard treatment and in which, in the opinion of the investigator, experimental treatment with BAY1895344 may be of benefit, Furthermore, no standard therapy would confer clinical benefit to the patient.
  -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  -  Patients must have adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 (±2) days before the first dose of study drug:
  1. Hemoglobin ≥ 8.5 g/dL; patients with chronic erythropoietin treatment consistent with institutional guidelines can be included.
  2. Absolute neutrophil count (ANC) ≥ 1.5X10* 9/L (≥ 1500/mm3)
  3. Platelet count ≥ 100X10*9/L (≥100,000/mm3)
  Exclusion Criteria:
  -  Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study
  -  History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class >II, unstable angina (angina symptoms at rest), new-onset angina (within the past 6 months before study entry), myocardial infarction within the past 6 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted)
  -  Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C
  -  Patients with known human immunodeficiency virus (HIV) infection
  -  Patients who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. Patients with chronic HBV or HCV infection are eligible at the investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.
  -  Infections of CTCAE(Common Terminology Criteria for Adverse Events Version) Grade 2 not responding to therapy or active clinically serious infections of CTCAE Grade >2

Relevance to patient case: not relevant